- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02310022
A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules (PK/PD)
October 8, 2020 updated by: Matinas Biopharma, Inc
A Pharmacokinetic and Pharmacodynamic Study of Two Formulations of Omega-3 One Gram Capsules After Single and Multi-Dose Administrations Under Fed Conditions
Comparative bioavailability and pharmacodynamics effects of MAT9001 versus an active omega-3 medication comparator.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The primary objective is to determine the comparative bioavailability and pharmacodynamics effects of single and multiple doses of MAT9001 versus an active omega-3 medication comparator.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M1S 3V6
- Pharma Medica Reserach Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects must fulfil all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified:
- Adult male or female subject, 18-70 years of age, inclusive.
- Light- or non-smoking, male and female subjects, 18 to 70 years of age. Note: subjects that regularly smoke greater than 10 cigarettes per day will not be considered light-smokers and should not be included. Additionally, the use of any cigars, pipes, vapor inhalers or any other tobacco containing product is prohibited within 6 months prior to drug administration.
- Body mass index (BMI) ≥ 19 and ≤ 40 (kg/m2).
- No clinically significant findings in vital signs measurements. The acceptable range for seated systolic blood pressure is 90-150 mmHg and for diastolic blood pressure is 50-95 mmHg.
- No clinically significant abnormal laboratory values that, in the opinion of the investigator, would compromise the subject's safety or the integrity of the study results.
- Either have: elevated triglyceride levels (2.26 to 4.52 mmol/L [200 to 400 mg/dL]), or · triglyceride levels 2.26 to 3.95 mmol/L (200 to 350 mg/dL) and are on stable statin therapy.
- Total cholesterol levels ≤ 7.75 mmol/L (≤ 300 mg/dL).
- Hemoglobin ≥ 135 g/L for males or ≥ 120 g/L for females at screening.
- No clinically significant findings in a 12-lead electrocardiogram (ECG)
- Have no significant diseases.
- Willing to use an acceptable, effective method of contraception.
- Be informed of the nature of the study and give written consent prior to any study procedure.
- Have no clinically significant findings from a physical examination.
Exclusion Criteria:
Subjects may be excluded from the study if there is evidence of any of the following criteria at screening, check-in, or at any time during the study, as appropriate:
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal (GI), endocrine, immunologic, dermatologic, neurological, or psychiatric disease in the opinion of the PI.
- Personal or familial history of bleeding disorder(s), thromboembolic disease, clinical GI bleeding, or any history of GI surgery except uncomplicated appendectomy or cholecystectomy, or colorectal surgery for polyps, nonmalignant tumors, or diverticula.
- Positive urine drug/alcohol testing at screening or check-in.
- Positive result for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).
- History or presence of alcoholism or drug abuse within the past 2 years.
- Known sensitivity or allergy to fish, shellfish, gelatin or omega-3 products.
- Subject is a female who is pregnant or lactating.
- Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to drug administration
- Donation of blood or significant blood loss within 56 days prior to check- in.
- Participation in another clinical trial within 30 days prior drug administration.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drug Omega 3
4g (4 capsules) once a day, administered with food Other name MAT9001
|
4 g (4 capsules) once a day, administered with food
Other Names:
|
Active Comparator: Drug Omega 3 Comparator
4g (4 capsules) once a day, administered with food Other name Omega 3 Active Comparator
|
4 g (4 capsules) once a day, administered with food
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bioavailability comparison after single and multiple doses over a 24 hour period at day 1 and day 14
Time Frame: 14 Days
|
Area under the plasma concentration curve versus time curve (AUC0-tau) versus time curve (AUC0-tau) for both treatments measured over the 24 hour period on day 1 and day 14 [ Time Frame: 14 days ]
|
14 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of baseline changes of triglycerides and other related lipid protein parameter levels over 14 days
Time Frame: 14 Days
|
To compare the change from baseline triglyceride and other related lipid/lipoprotein parameter levels between:· MAT9001 and an active omega-3 medication comparator; after multi-dose administrations in subjects under fed conditions
|
14 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Eric Chen, MD, Pharma Medica Research, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Actual)
May 1, 2015
Study Completion (Actual)
August 1, 2016
Study Registration Dates
First Submitted
November 14, 2014
First Submitted That Met QC Criteria
December 3, 2014
First Posted (Estimate)
December 5, 2014
Study Record Updates
Last Update Posted (Actual)
October 12, 2020
Last Update Submitted That Met QC Criteria
October 8, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MB-70001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertriglyceridemia
-
Arrowhead PharmaceuticalsNot yet recruitingSevere Hypertriglyceridemia
-
89bio, Inc.RecruitingSevere HypertriglyceridemiaUnited States, Bulgaria, Canada, Latvia, Spain, Austria, Belgium, Czechia, Georgia, Hungary, Poland, Puerto Rico, Argentina, Chile, France, Germany, United Kingdom
-
Ionis Pharmaceuticals, Inc.RecruitingSevere HypertriglyceridemiaUnited States, Germany, Israel, Spain, Netherlands, Australia, Hungary, Sweden, Denmark, Canada, France, Italy, Turkey, Finland, Bulgaria, Czechia, New Zealand, Norway, Poland, Portugal, Slovakia, South Africa, United Kingdom
-
Sancilio and Company, Inc.WithdrawnSevere Hypertriglyceridemia
-
Arrowhead PharmaceuticalsCompletedSevere HypertriglyceridemiaUnited States, Netherlands, Australia, Canada, New Zealand, Poland, Hungary, Germany
-
AstraZenecaCompletedSevere HypertriglyceridemiaUnited States, Hungary, India, Russian Federation, Denmark, Ukraine, Netherlands
-
AstraZenecaRadiant ResearchCompletedSevere HypertriglyceridemiaUnited States
-
Trygg Pharma, Inc.UnknownSevere HypertriglyceridemiaUnited States
-
National Taiwan University HospitalUnknownHypertriglyceridemia During PregnancyTaiwan
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
Clinical Trials on Drug Omega 3
-
Zhejiang UniversityUnknownHyperlipidemias | Hyperglycaemia (Diabetic)China
-
University of CincinnatiDSM Nutritional Products, Inc.Completed
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
Pennington Biomedical Research CenterCompleted
-
AstraZenecaCompletedDiabetes Mellitus, Type 2 | Exocrine Pancreatic InsufficiencySweden, Poland, Latvia, Denmark, Hungary, Slovakia
-
Appalachian State UniversityCompleted
-
Seoul National University HospitalUnknown
-
Université de SherbrookeNot yet recruiting
-
Collegium Medicum w BydgoszczyUnknownChronic Kidney Disease | Cardiovascular ComplicationsPoland
-
Sunnybrook Health Sciences CentreAstraZenecaWithdrawnCOVID-19 | Chronic Lymphocytic LeukemiaCanada